Drug Overview

The Today Vaginal Contraceptive, commonly known as the contraceptive sponge, is an accessible, non-hormonal option within the Gynecology category. It empowers women to take control of their reproductive health right before intercourse, without the need for a daily pill or long-acting implant.

Belonging to the Vaginal Spermicide (Sponge) class, it provides localized protection against unintended pregnancy. It is a soft, disk-shaped device made of polyurethane foam that contains a sperm-killing chemical. Because it works locally within the vagina and does not release hormones into the bloodstream, it is an excellent choice for women who cannot or choose not to use systemic hormonal birth control.

Generic Name: Nonoxynol-9 (contained within a polyurethane sponge)
US Brand Name: Today Sponge
Drug Class: Vaginal Spermicide (Sponge)
Route of Administration: Intravaginal
FDA Approval Status: FDA-Approved (Available Over-The-Counter)

What Is It and How Does It Work? (Mechanism of Action)

Unlike systemic birth control pills, the Today Vaginal Contraceptive is not a Hormone Modulator and does not affect the hypothalamic-pituitary-ovarian (HPO) axis or ovulation. Instead, it relies on localized, physical, and chemical mechanisms to prevent fertilization.

It provides triple-action pregnancy protection:

Spermicidal Action at the Cellular Level: The sponge contains 1000 mg of nonoxynol-9, a nonionic surfactant. At the molecular level, this chemical interacts with the lipid (fat) bilayer of the sperm’s cell membrane. It acts like a detergent, breaking down the sperm’s outer wall, particularly the acrosomal membrane. This disruption instantly paralyzes the sperm and destroys its ability to swim or survive.
Physical Barrier: When inserted deep into the vagina, the sponge covers the opening of the cervix (the entrance to the uterus). This physical block prevents surviving sperm from traveling up into the reproductive tract.
Seminal Absorption: The dense polyurethane foam material actively absorbs semen upon ejaculation, trapping sperm inside the sponge and keeping it away from the cervix.

FDA-Approved Clinical Indications

The Today Vaginal Contraceptive is designed specifically for local, on-demand use.

Primary Gynecological/Obstetric Indications

Local Pregnancy Prevention: The sole FDA-approved use is the prevention of pregnancy in women of reproductive age. It is intended to be used directly before sexual intercourse.

Off-Label / Endocrinological Indications

Because this method is strictly local and non-hormonal, it has no endocrinological (hormone-balancing) or oncological uses. Its secondary uses remain focused on reproductive family planning:

Adjunct Contraception: Often used off-label in combination with other methods (like condoms or fertility awareness methods) to increase overall contraceptive effectiveness.
Backup Contraception: Used as a backup method when a primary hormonal method has been compromised (e.g., missed birth control pills).

Dosage and Administration Protocols

The sponge must be properly activated and correctly timed to ensure maximum effectiveness.

Timing / Phase	Device Formulation	Active Ingredient	Dosage	Administration Instructions
Pre-Intercourse	Polyurethane Foam Sponge	Nonoxynol-9	1000 mg per sponge	Moisten the sponge thoroughly with clean tap water and squeeze gently once to activate the spermicide. Insert deep into the vagina against the cervix before intercourse.
Post-Intercourse	Polyurethane Foam Sponge	Nonoxynol-9	N/A (Already in place)	The sponge must remain in place for at least 6 hours after the last act of intercourse. Do not leave the sponge in for more than 30 hours total.

Important Dosage Adjustments and Considerations:

Hepatic or Renal Insufficiency: Because nonoxynol-9 is not absorbed into the bloodstream in significant amounts, no dosage adjustments are needed for women with liver or kidney issues.
Parity (Prior Childbirth): The effectiveness of the sponge changes depending on whether a woman has given birth. Women who have given birth vaginally may have a slightly altered cervical shape, which can reduce the physical barrier effectiveness of the sponge.

Clinical Efficacy and Research Results

Current clinical guidelines (2020-2026) reaffirm the established effectiveness of the vaginal contraceptive sponge, evaluating it based on whether a woman has previously given birth (parity). Efficacy is tracked using failure rates (pregnancies per 100 women over one year of use).

Nulliparous Women (Women who have never given birth): The sponge is highly effective in this group. With perfect use, the failure rate is approximately 9 percent. With typical, real-world use, the failure rate is approximately 12 percent.
Parous Women (Women who have given birth): Efficacy decreases for women who have had a vaginal delivery. Perfect use failure rates are around 20 percent, and typical use failure rates can range from 24 percent to 27 percent.

Recent reproductive research emphasizes that while the sponge is a reliable non-hormonal option, its efficacy is significantly improved when paired with a male condom.

Safety Profile and Side Effects

WARNING: TOXIC SHOCK SYNDROME (TSS)

While rare, the use of vaginal sponges has been associated with Toxic Shock Syndrome, a severe and potentially life-threatening bacterial infection. To reduce this risk, the sponge must not be left in the vagina for more than 30 hours total. It should not be used during menstruation (your period) or shortly after childbirth, miscarriage, or abortion.

Common Side Effects (Occurring in >10% of users)

These side effects are typically local and mild:

Vaginal burning, irritation, or itching (often an allergic reaction or sensitivity to nonoxynol-9)
Vaginal dryness
Increased risk of urinary tract infections (UTIs) or yeast infections
Partner irritation (mild penile burning)

Serious Adverse Events

Toxic Shock Syndrome (TSS): Symptoms include sudden high fever, vomiting, diarrhea, dizziness, fainting, and a rash that looks like a sunburn.
Increased Risk of STIs: Frequent use of nonoxynol-9 (multiple times a day) can irritate the vaginal wall and cause microscopic mucosal abrasions. These tiny tears can actually increase a woman’s risk of contracting HIV and other sexually transmitted infections (STIs) if exposed.

Management Strategies:

If mild vaginal irritation occurs, the user should remove the sponge; if symptoms persist with subsequent uses, they may need to switch to a different non-hormonal method. If any signs of TSS occur, the patient must remove the sponge immediately and seek emergency medical care.

Research Areas

Because the contraceptive sponge is a localized physical barrier and chemical agent, it does not involve stem cell or regenerative medicine. However, ongoing Targeted Therapy and drug delivery research in women’s health is heavily focused on the vaginal microbiome and mucosal immunity. Current clinical research aims to develop newer, non-detergent spermicides and vaginal gels (such as those using lactic acid to naturally lower vaginal pH) that immobilize sperm without damaging the vaginal epithelium. This protects the local microbiome and eliminates the risk of microscopic tissue damage associated with older surfactants like nonoxynol-9.

Disclaimer: The research mentioned regarding “non-detergent spermicides” and lactic-acid-based vaginal gels is currently an active area of investigation in microbicide and contraceptive research. While products like Phexxi (a pH-modulating gel) are currently available, the development of next-generation “non-detergent” sponges remains exploratory and is not yet part of standard clinical practice or validated for professional medical decision-making in 2026.

Patient Management and Practical Recommendations

Using a localized, on-demand contraceptive requires user education to ensure it is inserted and timed correctly.

Pre-Treatment Tests

No specific baseline labs are required since this is an over-the-counter, non-hormonal product.
A routine gynecological exam is encouraged to ensure no anatomical anomalies would prevent proper placement over the cervix.

Precautions During Treatment

Post-Pregnancy Precautions: Do not use the sponge within 6 weeks of giving birth, or shortly after a miscarriage or abortion, without consulting a physician.
TSS Vigilance: Patients must be educated on the symptoms of Toxic Shock Syndrome and instructed strictly on the 30-hour maximum wear time.

Do’s and Don’ts

DO wet the sponge with clean water and squeeze it gently to activate the spermicide before insertion.
DO ensure the dimpled side of the sponge is facing the cervix when inserted.
DO leave the sponge in place for at least 6 hours after the last time you have intercourse.
DON’T use the sponge while you are menstruating.
DON’T use the sponge if you have a history of Toxic Shock Syndrome.
DON’T assume the sponge protects against HIV or other STIs. It does not; condoms are required for infection protection.

Legal Disclaimer

The content provided in this guide is intended for informational and educational purposes only. It is not meant to serve as a substitute for professional medical advice, diagnosis, or treatment. Always seek the direct advice of your physician, gynecologist, or other qualified healthcare provider regarding any questions or concerns you may have about a medical condition, birth control options, or before starting or stopping any medication.